Filtered By:
Drug: Temodar
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 1478 results found since Jan 2013.
Proteomic and metabolomic analyses illustrate the mechanisms of expression of the O < sup > 6 < /sup > -methylguanine-DNA methyltransferase gene in glioblastoma
CONCLUSION: This study provides novel mechanisms to understand methylation in GBM and identifies some biomarkers for the prognosis of two different GBM types, MGMT promoter unmethylated or methylated GBM, by using metabolomics and proteomics analyses.PMID:37641495 | DOI:10.1111/cns.14415
Source: CNS Neuroscience and Therapeutics - August 29, 2023 Category: Neuroscience Authors: Xi Chen Jinli Sun Yukui Li Weichao Jiang Zhangyu Li Jianyao Mao Liwei Zhou Sifang Chen Guowei Tan Source Type: research
Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma
CONCLUSION: Apparent survival benefit of extended adjuvant TMZ in newly diagnosed GBM is largely driven by nonrandomized comparative studies with high inherent potential for multiple biases.PMID:37638346 | PMC:PMC10457033 | DOI:10.1093/noajnl/vdad086
Source: Adv Data - August 28, 2023 Category: Epidemiology Authors: Tejpal Gupta Jeevi Mona Priyadharshni Selvarajan Sadhana Kannan Nandini Menon Archya Dasgupta Abhishek Chatterjee Source Type: research
Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
In conclusion, we demonstrate targeted RNA-guided methylation of the MGMT promoter as a promising tool to overcome chemoresistance and improve the cytotoxic effect of TMZ in glioblastoma.PMID:37634280 | DOI:10.1016/j.neo.2023.100929
Source: Neoplasia - August 27, 2023 Category: Cancer & Oncology Authors: Xinyu Han Mohammed O E Abdallah Peter Breuer Fabian Stahl Yousuf Bakhit Anna-Laura Potthoff Barbara E F Pregler Matthias Schneider Andreas Waha Ullrich W üllner Bernd O Evert Source Type: research
Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma
J Cell Mol Med. 2023 Aug 18. doi: 10.1111/jcmm.17907. Online ahead of print.ABSTRACTGlioblastoma (GBM) is an aggressive brain cancer with a poor prognosis. While surgical resection is the primary treatment, adjuvant temozolomide (TMZ) chemotherapy and radiotherapy only provide slight improvement in disease course and outcome. Unfortunately, most treated patients experience recurrence of highly aggressive, therapy-resistant tumours and eventually succumb to the disease. To increase chemosensitivity and overcome therapy resistance, we have modified the chemical structure of the PFI-3 bromodomain inhibitor of the BRG1 and BRM...
Source: J Cell Mol Med - August 18, 2023 Category: Molecular Biology Authors: Chuanhe Yang Yali He Yinan Wang Peter J McKinnon Vijay Shahani Duane D Miller Lawrence M Pfeffer Source Type: research
EZH2-regulated PARP 1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide
CONCLUSION: EZH2 PARP 1 signaling axis is possibly responsible for the chemoresistance of gliomas to TMZ. Simultaneously inhibiting these two genes may improve the outcome of TMZ chemotherapy.PMID:37594167 | DOI:10.2174/1568009623666230818151830
Source: Current Cancer Drug Targets - August 18, 2023 Category: Cancer & Oncology Authors: Qiang Liang Bing Wang Chenran Zhang Chaoli Song Junyu Wang Wei Sun Lei Jiang Jing Lin Source Type: research
Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma
J Cell Mol Med. 2023 Aug 18. doi: 10.1111/jcmm.17907. Online ahead of print.ABSTRACTGlioblastoma (GBM) is an aggressive brain cancer with a poor prognosis. While surgical resection is the primary treatment, adjuvant temozolomide (TMZ) chemotherapy and radiotherapy only provide slight improvement in disease course and outcome. Unfortunately, most treated patients experience recurrence of highly aggressive, therapy-resistant tumours and eventually succumb to the disease. To increase chemosensitivity and overcome therapy resistance, we have modified the chemical structure of the PFI-3 bromodomain inhibitor of the BRG1 and BRM...
Source: J Cell Mol Med - August 18, 2023 Category: Molecular Biology Authors: Chuanhe Yang Yali He Yinan Wang Peter J McKinnon Vijay Shahani Duane D Miller Lawrence M Pfeffer Source Type: research
